The control and the role of DAMPs in acute and chronic renal injury
| Project/Area Number |
26461615
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
細矢 光亮 福島県立医科大学, 医学部, 教授 (80192318)
橋本 浩一 福島県立医科大学, 医学部, 准教授 (50322342)
陶山 和秀 福島県立医科大学, 医学部, 講師 (90423798)
大原 信一郎 福島県立医科大学, 医学部, 助教 (00566846)
鈴木 順造 福島県立医科大学, 看護学部, 教授 (20171217)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | Acute renal injury / DAMPs / HUS / rhTM / HUSモデル / HMGB1 / VEGF / アンギオポエチン1 / 内皮細胞障害 / S100A8 / S100A9 |
|---|
| Outline of Final Research Achievements |
In order to clarify the efficacy of recombinant human soluble thrombomodulin(rhTM) for the treatment of typical hemolytic uremic syndrome(t-HUS), we examined changes in renal damage in t-HUS mice treated with rhTM or vehicle alone. We used severe and moderate t-HUS mice injected with shiga toxin(Stx) and lipopolysaccharide(LPS). The severe t-HUS mice were divided into two subgroups [an rhTM subgroup(Group A) and a saline subgroup(Group B)] along with the moderate t-HUS mice [an rhTM subgroup(Group C) and a saline subgroup(Group D)]. Groups E and F were healthy animals mice treated with rhTM or saline, respectively.
All mice in Group A remained alive. Serum creatinine level, and endothelial injury scores in the t-HUS mice treated with rhTM were lower than those in t-HUS mice treated with saline. Serum IL-6, TNF-α, and FDP levels at 24 hours after administration in Group A were lower than those in Group B. These results indicate that rhTM might afford an efficacious treatment for t-HUS.
|
Report
(4 results)
Research Products
(11 results)
-
-
-
[Journal Article] Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis2016
Author(s)
Kawasaki Y, Kanno S, Ono A, Suzuki Y, Ohara S, Sato M, Suyama K, Hashimoto K, Hosoya M
-
Journal Title
Pediatr Nephrol
Volume: 31
Issue: 7
Pages: 1091-1099
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
